Financial Review: RxSight (NASDAQ:RXST) & Cerus (NASDAQ:CERS)

RxSight (NASDAQ:RXST) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Profitability

This table compares RxSight and Cerus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Cerus	-3.06%	-10.19%	-3.14%

Valuation and Earnings

This table compares RxSight and Cerus”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48 million	1.44	-$38.94 million	($1.13)	-4.12
Cerus	$206.13 million	2.56	-$15.63 million	($0.03)	-87.33

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

RxSight has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Cerus has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for RxSight and Cerus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3	7	2	0	1.92
Cerus	1	1	3	0	2.40

RxSight presently has a consensus target price of $8.17, indicating a potential upside of 75.37%. Cerus has a consensus target price of $5.25, indicating a potential upside of 100.38%. Given Cerus’ stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than RxSight.

Institutional and Insider Ownership

78.8% of RxSight shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 5.3% of Cerus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cerus beats RxSight on 11 of the 14 factors compared between the two stocks.

About RxSight

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.